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Introduction {#cjp274-sec-0001}
============

Tumour vasculature impacts on multiple aspects of tumour biology [1](#cjp274-bib-0001){ref-type="ref"}, [2](#cjp274-bib-0002){ref-type="ref"}. The vasculature of solid tumours affects growth and metastasis propensity. Interactions between vascular cells and immune cells also impact on immune surveillance. Furthermore, vascular properties regulate chemotherapy sensitivity by affecting drug delivery.

Analyses of properties such as vessel density, vessel maturation, endothelial cell proliferation, marker expression, and pericyte status have demonstrated that these features are associated with prognosis in many tumour types, such as breast, prostate, ovarian, clear cell renal cell carcinomas, and glioblastoma [2](#cjp274-bib-0002){ref-type="ref"}, [3](#cjp274-bib-0003){ref-type="ref"}, [4](#cjp274-bib-0004){ref-type="ref"}, [5](#cjp274-bib-0005){ref-type="ref"}, [6](#cjp274-bib-0006){ref-type="ref"}.

Anti‐angiogenic treatments targeting VEGF receptor signaling have been tested in many different tumour types for treatment of metastatic disease or in adjuvant settings [7](#cjp274-bib-0007){ref-type="ref"}, [8](#cjp274-bib-0008){ref-type="ref"}. Results from these clinical studies have demonstrated tumour‐type‐specific differences in sensitivity to these drugs when used as mono‐treatments. Well‐known examples of tumour‐type‐specific differences in efficacy include, for example, the robust effects of mono‐treatment with anti‐angiogenic drugs in renal cell cancer [9](#cjp274-bib-0009){ref-type="ref"}, the modest effects in ovarian cancer [10](#cjp274-bib-0010){ref-type="ref"}, and the lack of effects in colorectal cancer [11](#cjp274-bib-0011){ref-type="ref"}.

These differences in sensitivity to anti‐angiogenic drugs could reflect systematic functional and structural differences in the tumour vasculature of different tumour types. Such differences could be caused by organ‐specific differences in physiological vascular biology programme. It can also be envisioned that tumour‐type‐specific oncogenic drivers are initiating different angiogenic programmes. Furthermore, results from studies of metastatic lesions show that different tumour types use angiogenesis or vessel co‐option to varying degrees, presenting vasculatures with different degree of maturation [12](#cjp274-bib-0012){ref-type="ref"}, [13](#cjp274-bib-0013){ref-type="ref"}. Systematic comparisons of vascular biology features between different tumour types therefore have the potential to uncover tumour‐type‐specific features of vascular biology with mechanistic or therapeutic potential.

Most prognosis studies with vascular markers have used case‐based mean‐values of the marker‐of‐interest as the basis for scoring of individual tumours. Recent analyses in ovarian and kidney cancer have demonstrated that the inside‐case heterogeneity regarding expression of a perivascular marker acts as a prognostic factor [14](#cjp274-bib-0014){ref-type="ref"}. This suggests the possibility of prognostic significance also of heterogeneity of other tumour vasculature characteristics.

This study exploits a set of integrated procedures for quantification of vascular characteristics, which recently uncovered novel vascular biomarkers and suggested novel biological mechanisms in ovarian, renal cell, and colorectal cancer [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}, [15](#cjp274-bib-0015){ref-type="ref"}. In this study, data from four tumour collections (colorectal cancer cohort, colon cancer cohort, ovarian cancer, and kidney cancer cohorts) have been used to compare vascular characteristics between tumour types. Furthermore, the previous demonstration of prognostic significance of perivascular heterogeneity has been extended to analyses of the potential prognostic significance of 'vessel distance IQR'; a 'metric' capturing intra‐case heterogeneity regarding inter‐vessel distances [14](#cjp274-bib-0014){ref-type="ref"}.

Material and methods {#cjp274-sec-0002}
====================

Tumour cohorts and tissue micro‐arrays {#cjp274-sec-0003}
--------------------------------------

Details about the tumour cohorts have been described previously [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}, [16](#cjp274-bib-0016){ref-type="ref"}. In brief, the ovarian cancer collection (OC) is composed of 109 cases of primary adnexal site tissues deriving from patients affected by serous ovarian cancer collected consecutively between 1985 and 2006 at the University Medical center Groningen (Groningen, The Netherlands) [17](#cjp274-bib-0017){ref-type="ref"}. The renal cell cancer collection (RCC) is composed of 288 primary tumours from surgically treated patients diagnosed at Malmo University Hospital (current Skåne University Hospital), between 1978 and 1996 [14](#cjp274-bib-0014){ref-type="ref"}. The colorectal cancer collection (CRC) is composed of primary tumours from 447 patients diagnosed in Malmo University Hospital. This cohort originates from the population‐based prospective study, the Malmo Diet and Cancer Cohort, that enrolled individuals between 1991 and 1996 [16](#cjp274-bib-0016){ref-type="ref"}. The colon cancer cohort was made up of primary tissues derived from 93 patients from a Nordic randomized clinical trial performed to evaluate the efficacy of 5‐FU (5‐fluorouracil)‐based adjuvant chemotherapy [18](#cjp274-bib-0018){ref-type="ref"}. The original study included 2224 patients younger than 76 years with stages II‐III colon cancer radically resected in 1991 -- 1997. The present study is based on a selection from the original study of Swedish cases of colon cancer. No patient received radiotherapy or chemotherapy prior to surgery.

All tissues were collected prior to chemotherapy treatment. Preparation of tissue micro‐arrays followed standard procedures and is described in previous publications [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}, [16](#cjp274-bib-0016){ref-type="ref"}, [17](#cjp274-bib-0017){ref-type="ref"}. In the different TMAs, each case is represented by two (colorectal and kidney) or up to four (ovarian cancer) 'tissue punches'. TMA preparation was approved by appropriate ethical committees.

Ethical approvals have been obtained (Dnr 530/2008 for the colorectal collection, Malmo Diet and Cancer Cohort; Dnr 00--260, 2014/664--32 for the Mammoth CRC‐cohort, Dnr 282/2007 for the renal cell cancer collection Skåne University Hospital; Dnr 2016/551--32 for the ovarian cancer collection, original certification can be provided by Dr G. Bea A. Wisman).

Immunohistochemistry and slide scanning {#cjp274-sec-0004}
---------------------------------------

Procedures for double staining with PDGFR‐β/α‐SMA and CD34 antibodies have been described earlier together with details of the α‐SMA detection antibody [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}, [15](#cjp274-bib-0015){ref-type="ref"}. The antibody used for PDGFR‐β detection was 28E1 Rabbit mAb, 3169, Cell Signaling Technology. CD34 stains were performed with the antibody clone QBEnd 10, M7165 Mouse mAb, DAKO [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}, [15](#cjp274-bib-0015){ref-type="ref"}. Detection of primary antibodies followed standard procedures as described previously. Stained slides were subsequently scanned using a Vslide scanning microscope (Metasystems, Alltlussheim, Germany).

Specificity of the PDGF‐β‐receptor antibody has been extensively characterized in earlier studies, including test‐staining of sections of paraformaldehyde‐fixed paraffin‐embedded cultured cells of known PDGF receptor status [19](#cjp274-bib-0019){ref-type="ref"}.

Images analyses {#cjp274-sec-0005}
---------------

Images were analyzed with ImageJ software using an algorithm developed in‐house [14](#cjp274-bib-0014){ref-type="ref"}, [15](#cjp274-bib-0015){ref-type="ref"}. Subsequent data analysis was performed with R (R 3.2.2 GUI 1.66 Mavericks build (6996) <http://www.R-project.org>).

CD34 staining was used to determine vessel density, vessel diameter, and vessel distance to the nearest vessel. α‐SMA‐ and PDGFR‐β‐staining were used as markers for cancer‐associated fibroblasts and perivascular cells.

Perivascular area was defined as the region circumjacent to, and extending 5.5 µm away from, the vessel. The intensity of perivascular marker expression (α‐SMA or PDGFR‐β) was measured in each such area. A case‐based value was obtained (perivascular intensity (PVI) by calculating the median intensity for all perivascular areas of each case (see Frödin *et al* for more details [14](#cjp274-bib-0014){ref-type="ref"}).

Marker‐positive stroma fraction was defined as the fraction of the analyzed sample, excluding perivascular regions (see above) and vessel regions, that displayed an expression level above a threshold level. (see Frodin *et al* for more details [14](#cjp274-bib-0014){ref-type="ref"}).

For scoring of PDGFR‐β intensity, we used a tumour‐type‐specific scale to accommodate potential systematic differences between the cohorts regarding, for example, tissue quality and antigen preservation. The intensity was determined within each tumour type using a scale ranging from 0 to 1 with 0 as the lowest noted intensity and 1 as the highest detected intensity. This enabled comparison between tumour types regarding how cases were distributed within each tumour‐specific scale.

A set of procedures was used to obtain a value for each case that would be related to vessel density heterogeneity. First, distance to closest vessel was determined for all vessels of all cases. Second, a median‐based value for vessel‐distance was determined for each case. Third, to quantitate the intra‐case heterogeneity of vessel distribution, the difference between first and third quartiles were calculated for each case. This metric was designated 'vessel distance IQR'.

Data processing {#cjp274-sec-0006}
---------------

For comparison between tumour types for marker‐intensity‐related metrics, the original data for each tumour type was normalized and given values between 0 and 1. Normalization was performed case‐wise for fibroblast‐dominated stroma intensity and vessel‐wise for perivascular status. Normalization addressed the issue of skewed distribution of data by skewness adjustment as described by Vanderviere [20](#cjp274-bib-0020){ref-type="ref"} and 'vessel distance IQR' metrics were dichotomized per the median.

Statistical analyses {#cjp274-sec-0007}
--------------------

All tests were carried out at the 95% statistical significance level and were performed using SPSS versions 22 and 23 (SPSS Inc., Chicago, IL) and Rstudio (Version 0.99.489 -- © 2009--2015 RStudio, Inc.)

Differences between tumour types regarding case‐based values for fibroblast‐dominated stroma metrics, as analyzed in in Figure [1](#cjp274-fig-0001){ref-type="fig"}, were determined using the Mann‐Whitney U test. Correlations between case‐based stroma metrics, as analyzed in Figure [2](#cjp274-fig-0002){ref-type="fig"}, were determined using the Spearman correlation test for pair‐wise analyses. Log Rank Tests and Cox Regression Models were used to estimate relationships between analyzed metrics and overall survival (Figure [4](#cjp274-fig-0004){ref-type="fig"}, Table [1](#cjp274-tbl-0001){ref-type="table-wrap"}, and supplementary material, Table S3). Associations with the clinico‐pathological characteristics were evaluated with Pearson\'s Chi Square test (supplementary material, Table S2a--c).

![Comparisons of CRC, RCC, and OC regarding case‐based values for vascular and stroma features. Box plots comparing CRC, RCC, and OC tumours with regard to case‐based values for stroma features. The tumour stroma features analyzed are (A) mean intensity of stromal PDGFR‐β‐expression; (B) abundance of PDGFR‐β‐positive tumour stroma; (C) vessel density; (D) mean vessel size; (E) vessel size heterogeneity; (F) heterogeneity regarding inter‐vessel distances, 'vessel distance IQR'; (G) mean intensity of perivascular PDGFR‐β‐expression; and (H) heterogeneity regarding perivascular PDGFR‐β‐expression. For procedures used to obtained case‐based values for these stroma features, see Material and Methods section.](CJP2-3-214-g001){#cjp274-fig-0001}

![Comparisons of CRC, RCC, and OC regarding correlations between different stroma features. (A) Panels illustrate pair‐wise correlation analyses of case‐based values for stroma features in CRC (upper), RCC (middle), and OC (lower). The left part contains analyses of the correlations between vascular features (vessel density, vessel diameter, and mean intensity of perivascular PDGFR‐β‐expression \[PDGFR‐β PVI\]) and abundance of PDGFR‐β‐positive tumour stroma (PDGFR‐β‐positive stroma fraction). The right part contains analyses of the correlations between the three different vascular features. For procedures used to obtained case‐based values for these stroma features, see Material and Methods section. (B) The graph illustrates the relationship between vessel diameter and perivascular PDGFR‐β‐intensity in vessels of CRC, RCC, and OC using vessel‐based values. For details concerning methods to obtain data for perivascular PDGFR‐β‐status and diameter of individual vessels, see Material and Methods.](CJP2-3-214-g002){#cjp274-fig-0002}

###### 

Uni‐ and multivariate Cox regression analyses of survival association of 'vessel distance IQR' and clinical characteristics in RCC

  Variables              Univariate analysis   Multivariate analysis                        
  ---------------------- --------------------- ----------------------- -------------------- -------
  Age at diagnosis                                                                          
   \<50                  1 (reference)         0.01                    1 (reference)        0.03
   \>50                  2.11(1.17--3.81)                              2.94 (1.08--8.00)    
  Gender                                                                                    
   Female 0              1 (reference)         0.80                    1 (reference)        0.82
   Male 1                1.04 (0.76--1.42)                             0.93 (0.50--1.72)    
  T stage                                                                                   
   1                     1 (reference)         0.11                    1 (reference)        0.36
   2                     2.56 (0.82--8.06)     0.035                   2.15 (0.43--10.82)   0.05
   3                     3.38 (1.09--10.48)    \< 0.001                4.63 (0.99--21.74)   0.003
   4                     12.1 (4.31--33.99)                            9.87 (2.16--45.20)   
  M stage                                                                                   
   0                     1 (reference)         \<0.001                 1 (reference)        0.002
   1                     6.22 (4.29--9.02)                             3.6 (1.60--8.10)     
  Fuhrman grade                                                                             
   1                     1 (reference)         0.53                    1 (reference)        0.76
   2                     1.13 (0.71--1.51)     \<0.001                 1.14 (0.48--2.69)    0.21
   3                     2.49 (1.57--3.50)     \<0.001                 1.76 (0.72--4.26)    0.12
   4                     8.6 (5.12--14.84)                             2.61 (0.78--8.80)    
  Histology                                                                                 
   Non‐clear cell        1 (reference)         0.73                    1 (reference)        0.53
   Clear cell            1.14 (0.56--2.33)                             1.44 (0.47--4.47)    
  IQR vessel distances                                                                      
   Low                   1 (reference)         \<0.001                 1 (reference)        0.006
   High                  1.95 (1.42--2.68)                             2.46 (1.29--4.69)    

Results {#cjp274-sec-0008}
=======

Comparison between tumour types with regard to fibroblast‐dominated stroma and vascular features {#cjp274-sec-0009}
------------------------------------------------------------------------------------------------

The main analyses were performed on four different population‐based collections of primary tumours, which have been used in earlier biomarker studies (see Material and Methods and supplementary material, Table S1a--c for cohort descriptions, [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}). Initial analyses focused on comparing different vascular and fibroblast‐dominated stroma features between colorectal cancer (CRC), renal cell cancer (RCC) and ovarian cancer (OC; Figure [1](#cjp274-fig-0001){ref-type="fig"}A--D,G). Data were also used to compare intra‐case heterogeneity of vascular and perivascular features (Figure [1](#cjp274-fig-0001){ref-type="fig"}E,F,H; see Materials and Methods and [14](#cjp274-bib-0014){ref-type="ref"} for details concerning the metrics 'vessel size IQR' and 'perivascular intensity \[PVI\] IQR').

Fibroblast‐rich stroma {#cjp274-sec-0010}
----------------------

RCC displayed the statistically significantly highest expression levels of PDGFR‐β in the tumour stroma (Figure [1](#cjp274-fig-0001){ref-type="fig"}A). The fraction of tumour area positive for the fibroblast marker PDGFR‐β was highest in CRC (Figure [1](#cjp274-fig-0001){ref-type="fig"}B). Examples of cases with significantly high and low PDGFR‐β stroma fraction, from each of the three tumour types, are shown in supplementary material, Figure S1. Independent analyses using α‐smooth muscle actin as a fibroblast marker yielded similar results when tumour types were analyzed with regard to abundance of fibroblast‐rich stroma (supplementary material, Figure S2a).

Vessels {#cjp274-sec-0011}
-------

RCC cases displayed statistically significantly higher vessel density as compared to OC and CRC (Figure [1](#cjp274-fig-0001){ref-type="fig"}C). Concerning vessel size, analyses showed that both absolute values and intra‐case variation of vessel size were larger in OC in comparison to CRC and RCC (Figure [1](#cjp274-fig-0001){ref-type="fig"}D,E).

Perivascular cells {#cjp274-sec-0012}
------------------

CRC cases showed significantly higher absolute values and intra‐case variation of perivascular PDGFR‐β expression (Figure [1](#cjp274-fig-0001){ref-type="fig"}G,H). Examples of cases with high and low PDGFR‐β perivascular intensity, from each of the three tumour types, are shown in supplementary material, Figure S3. Independent analyses using α‐SMA as a marker for perivascular cells demonstrated that the tumour‐type‐related differences were not detected when this marker was used for perivascular cells (supplementary material, Figure S2b).

Associations between stroma and vascular metrics in each of the analyzed tumour types {#cjp274-sec-0013}
-------------------------------------------------------------------------------------

Case‐based values for vessel density, vessel size, and perivascular status were compared with regard to pair‐wise correlation within the different tumour types (Figure [2](#cjp274-fig-0002){ref-type="fig"}A, right part). Associations between vessel densities, vessel size and perivascular status were in general low, as described in our previous publications. However, in RCC, but not in CRC and OC, cases with higher vessel density were also characterized by lower perivascular status, resulting in moderate negative correlation (Spearman *r* = −0.43) between these two metrics (Figure [2](#cjp274-fig-0002){ref-type="fig"}A, right part).

Vessel characteristics were also compared to PDGFR‐β status in tumour fibroblast‐dominated stroma (Figure [2](#cjp274-fig-0002){ref-type="fig"}A, left part). These metrics showed strong positive correlations (Spearman *r* = 0.71, 0.67 and 0.83, respectively).

For additional analyses of potential relationships between vessel size and perivascular status, data were analysed in a vessel‐based, rather than case‐based manner. As shown in Figure [2](#cjp274-fig-0002){ref-type="fig"}B, these analyses confirmed the previous case‐based findings of the absence of strong correlation between vessel size and perivascular status in OC and RCC. In contrast, vessels in CRC displayed a more complicated pattern: perivascular expression of PDGFR‐β is highest in vessels of 5--15 µm diameter. For vessels bigger than 15 µm the intensity of the perivascular expression of PDGFR‐β appeared inversely correlated with vessel size.

High heterogeneity in vessel‐distribution is associated with poor survival in RCC and CRC {#cjp274-sec-0014}
-----------------------------------------------------------------------------------------

Previous analyses of the OC and RCC cohort have demonstrated that high heterogeneity of the perivascular status is associated with poor prognosis [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}. In the present study, we introduced a novel metric denoted 'vessel distance IQR', which describes the variation in distance to the closest located vessel for each vessel in a tumour sample. This novel metric was investigated regarding its association with other clinico‐pathological characteristics and with survival. Image examples of cores from the OC, RCC, and CRC cohorts with high and low 'vessel distance IQR' are shown in Figure [3](#cjp274-fig-0003){ref-type="fig"}.

![CRC, RCC, and OC cases with high or low inter‐vessel distance heterogeneity (vessel distance IQR). Photomicrographs showing examples of CRC (left), RCC (middle), and OC (right) tumours with high (upper) or low (lower) heterogeneity regarding inter‐vessel distances. Sections have been stained to detect endothelial cells with CD34 antibodies (red) and with PDGFR‐β antibodies (blue).](CJP2-3-214-g003){#cjp274-fig-0003}

The associations of 'vessel distance IQR' with standard clinico‐pathological characteristics are shown in supplementary material, Table S2a--c. In the CRC cohort, high heterogeneity of vessel density correlated significantly with female sex, advanced T‐ and M‐ stage and low differentiation grade (supplementary material, Table S2a). In RCC, high heterogeneity of vessel density was significantly associated with male sex and high Fuhrman grade (supplementary material, Table S2b). No significant association was found in the OC cohort between 'vessel distance IQR' or any of the clinico‐pathological characteristics (supplementary material, Table S2c).

Notably, as shown in the Kaplan‐Meier plots of Figure [4](#cjp274-fig-0004){ref-type="fig"}, high heterogeneity in vessel density was significantly associated with poor survival in both RCC and CRC (median survival 95 months versus 36 month, HR = 1.95 (Confidence Intervals at 95% CI95%: 1.42--2.68), *p* \< 0.001 and median survival 10.31 years versus 6.24 years, HR = 1.29 (CI95%: 1.00--1.67), *p* = 0.05, for RCC and CRC, respectively). Heterogeneity in vessel density in OC had no impact on survival (HR = 1.04 \[Cl95%: 0.66--1.64\], *p* = 0.86).

![Associations between heterogeneity of inter‐vessel‐distances and overall survival in CRC, RCC, and OC. Kaplan‐Meier curves for overall survival, with *P* values of Log Rank test, in CRC, RCC, and OC for cases defined by vessel distance IQR.](CJP2-3-214-g004){#cjp274-fig-0004}

In RCC and CRC, additional analyses tested the independence of vessel distance IQR from standard clinico‐pathological characteristics, by Cox uni‐ and multi‐variate analysis. As shown in Table [1](#cjp274-tbl-0001){ref-type="table-wrap"}, this novel metric acted as an independent marker of prognosis in RCC (HR = 2.46 \[CI95%: 1.29--4.69\], *p* = 0.006), but not in CRC (supplementary material, Table S3).

Explorative analyses were performed to investigate if vessel density heterogeneity showed differential prognostic significance in various subsets of RCC and CRC (supplementary material, Figure S4a,b). In RCC, the strongest association between high heterogeneity of vessel density and short survival was seen in the T stage IV and in clear cell histology (supplementary material, Figure S4a). The analyses of CRC indicated that the survival association of heterogeneity of vessel density was stronger in males as compared to females (supplementary material, Figure S4b).

Discussion {#cjp274-sec-0015}
==========

Through analyses of a large dataset, obtained from state‐of‐the‐art multi‐parametric stroma‐profiling of three clinically well‐annotated tumour collections, this study identifies different stroma phenotypes in three common types of cancers.

The major findings from the comparative analyses are summarized in Table [2](#cjp274-tbl-0002){ref-type="table-wrap"}. The defining properties of RCC include a high vessel density together with low abundance of PDGFR‐β‐positive tumour fibroblast‐dominated stroma. Vessels of RCC are in general small and display low perivascular PDGFR‐β expression. CRC is characterized by low vessel density, high abundance of PDGFR‐β‐positive fibroblast‐dominated stroma, and high perivascular PDGFR‐β‐positivity. OC presents a third phenotype including low vessel density, larger vessel size, low perivascular PDGFR‐β expression, and moderate amounts of PDGFR‐β‐positive fibroblast‐dominated stroma. Notably, the tumour‐type‐specific differences regarding perivascular status were not detected in analyses using alpha‐smooth‐muscle actin as a perivascular marker, confirming findings that these markers detect different subsets of perivascular cells [5](#cjp274-bib-0005){ref-type="ref"}, [14](#cjp274-bib-0014){ref-type="ref"}, [21](#cjp274-bib-0021){ref-type="ref"}.

###### 

Summary of stroma features in RCC, CRC, and OC

  Metric                                   RCC    CRC    OC
  ---------------------------------------- ------ ------ ------
  Vessel density                           High   Low    Low
  Vessel size                              Low    Low    High
  PDGFR‐β PVI                              Low    High   Low
  Stroma abundance                         Low    High   Low
  PDGFR‐β PVI/stroma correlation           High   High   High
  Vessel density/PDGFR‐β PVI correlation   High   Low    Low

The tumour‐type‐specific vessel properties indicate reliance on different angiogenic programmes. The high vessel density/low perivascular coverage phenotype of RCC is compatible with VEGF‐driven angiogenesis not balanced by a vessel‐maturation programme including recruitment of PDGFR‐β‐positive perivascular cells [22](#cjp274-bib-0022){ref-type="ref"}, [23](#cjp274-bib-0023){ref-type="ref"}. RCC furthermore displays an inverse relationship between vessel density and perivascular status -- a feature not observed in CRC or OC (Figure [2](#cjp274-fig-0002){ref-type="fig"}). This phenotype is possibly linked to the well‐established "VEGF‐high" characteristics of RCC, which occur as a consequence of VHL‐deficiency, and activation of HIF [24](#cjp274-bib-0024){ref-type="ref"}. In contrast, the vasculature of CRC has features of higher maturation and might thus reflect a strong involvement of physiological vascular programmes of the sub‐epithelial mucosa. This is compatible with the growth pattern of CRC, which involves invasion into the mucosa, which is composed of vascularized loose connective tissue.

Interestingly, the phenotypes emerging from these analyses correspond well to earlier described 'fibroblast‐dominated stroma phenotypes' which have been linked to the sensitivity to anti‐angiogenic therapy [25](#cjp274-bib-0025){ref-type="ref"}. The study of Smith *et al*, predominantly relying on analyses of different experimental tumour models, identified a 'tumour vessel' phenotype and 'fibroblast‐dominated stroma vessel phenotype' largely overlapping with the RCC‐OCand CRC phenotypes, respectively, of the present study. Notably, the 'tumour vessel'/RCC‐OC phenotype displayed a greater sensitivity to treatment with anti‐VEGF agent, in agreement with the clinical experience of efficiency of treatment with such drugs in RCC [26](#cjp274-bib-0026){ref-type="ref"} and in maintenance therapy of OC [10](#cjp274-bib-0010){ref-type="ref"}, [27](#cjp274-bib-0027){ref-type="ref"}, but not in CRC [11](#cjp274-bib-0011){ref-type="ref"}, [28](#cjp274-bib-0028){ref-type="ref"}. An implication of these findings, for possible future testing, is that 'outliers' of CRC with an RCC‐like tumour stroma might be sensitive to anti‐VEGF treatments. Furthermore, it could be tested whether the anti‐VEGF‐benefit in OC is particularly strong in cases displaying the most typical 'perivascular‐low' phenotype.

A series of recent studies have indicated that tumour metastasis relying on vessel co‐option displays a reduced sensitivity to anti‐VEGF‐agents [13](#cjp274-bib-0013){ref-type="ref"}, [29](#cjp274-bib-0029){ref-type="ref"}, [30](#cjp274-bib-0030){ref-type="ref"}, [31](#cjp274-bib-0031){ref-type="ref"}. Among the primary‐tumour‐derived vascular phenotypes of the present study, the CRC‐type vessels with high PDGFR‐β expression are most similar to the VEGF‐antagonist‐resistant co‐opted metastasis vessels. Future studies should also explore the presence of the CRC primary tumour vessel phenotype in metastatic lesions, and describe its sensitivity to VEGF‐antagonists.

Concerning mechanisms for 'fibroblast‐dominated stroma‐building' a strong intra‐case correlation of PDGFR‐β expression in fibroblast‐stroma and perivascular regions was noted (Figure 2, left panel). This indicates that related cells populate these compartments. This notion is supported by recent lineage‐tracing studies which have established strong links between perivascular cells and fibroblasts/myo‐fibroblasts in different settings [30](#cjp274-bib-0030){ref-type="ref"}, [32](#cjp274-bib-0032){ref-type="ref"}, [33](#cjp274-bib-0033){ref-type="ref"}, [34](#cjp274-bib-0034){ref-type="ref"}.

This study identified previously un‐recognized prognostic significance in RCC of a novel metric, 'vessel distance IQR', related to the distribution of vessels (Figure 4 and Table [1](#cjp274-tbl-0001){ref-type="table-wrap"}). It is recognized that this finding should be validated in independent RCC cohorts. It is noted as a limitation of the present study that analyses have been performed on cohorts with some samples dating back to the 1980s. Since then, new treatment strategies have been implemented such as bevacizumab and PARP‐inhibitors in OC, and tyrosine kinase inhibitors (TKIs) and check point inhibitors in RCC. Future studies on other cohorts should address potential response‐predictive significance of 'vessel distance IQR'. Such studies, if relying mostly on analyses of primary tumours for biomarkers predicting sensitivity of metastatic lesions to drug‐of‐interest, should also integrate analyses of the 'stability' of vascular and fibroblast features in matched primary tumours and metastatic lesions.

The finding of prognostic significance of 'vessel distance IQR' illustrates the potential of digital image‐analyses‐based scoring of vascular features for the development of features or 'metrics' that cannot be scored or detected with conventional visual inspection of stained tumour sections. It can be envisioned that continued analyses of the existing data‐set will allow generation of additional 'higher‐level' features of mechanistic relevance as well as biomarker significance. Such studies should also explore to what extent variations in tumour microenvironment composition can be explained by different changes in the cancer genome.

For future studies, it is noted that the profiling of the present study can be extended to additional features, such as vascular proliferation or marker‐defined subsets of perivascular and endothelial cells. Such studies, together with the collective findings of the present work, should contribute to the long‐term goal of exploiting tumour stroma variability for clinically meaningful tumour sub‐typing and patient stratification.
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**Supplementary figure legends**

###### 

Click here for additional data file.

###### 

**Figure S1.** Images showing examples of cases with low (a, c and f) or high (b,d and e) PDGFR‐β stroma fraction in renal cell carcinoma (RCC) (a,b), colorectal carcinoma (CRC) (c,d) and ovarian carcinoma (OC) (e,f)
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Click here for additional data file.

###### 

**Figure S2.** Box plots showing differences between the tumour types regarding a) stroma fraction and b) perivascular intensity for α‐SMA. RCC, renal cell carcinoma; OC, ovarian carcinoma
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Click here for additional data file.

###### 

**Figure S3.**. Images showing examples of cases with low (a, c and f) or high (b,d and e) PDGFR‐β perivascular intensity in renal cell carcinoma (RCC) (a,b), colorectal carcinoma (CRC) (c,d) and ovarian carcinoma (OC) (e,f)
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Click here for additional data file.

###### 

**Figure S4.** Associations between vessel heterogeneity of inter‐vessel‐distances and overall survival in subgroups of colorectal carcinoma and renal cell carcinoma. Forest‐plots showing the hazard ratios (HRs), including confidence intervals, for "vessel distance IQR" in subgroups of a) renal cell carcinoma and b) colorectal carcinoma
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Click here for additional data file.
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**Table S1.** Clinico‐pathological characteristics of patients in a) the renal cell carcinoma cohort, b) the colorectal carcinoma cohort, and c) the ovarian carcinoma cohort
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Click here for additional data file.
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**Table S2.** Associations with the clinico‐pathological characteristics of vessel distance IQR in a) colorectal carcinoma, b) renal cell carcinoma, and c) ovarian carcinoma
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**Table S3.** Multivariate Cox regression analyses of high and low IQR of vessel distances in colorectal carcinoma
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